Sector News

EC authorises LEO Pharma Anzupgo cream for chronic hand eczema

September 29, 2024
Life sciences

The European Commission (EC) has granted marketing authorisation to Leo Pharma’s Anzupgo (delgocitinib) cream for treating adults with moderate to severe chronic hand eczema (CHE).

The cream is indicated for use in CHE patients for whom topical corticosteroids are not suitable.

The approval extends to all member states of the European Union, Norway, Iceland and Liechtenstein.

The authorisation for Anzupgo cream is supported by data from the Phase III DELTA 1 and DELTA 2 clinical trials, which assessed the safety and efficacy of the cream versus a vehicle.

Both trials met their primary and all secondary endpoints.

LEO Pharma CEO Christophe Bourdon stated: “We are dedicated to advancing the standard of care for those living with skin conditions, and this long-awaited milestone for Anzupgo demonstrates our purpose in practice.

“This approval provides a new treatment option for patients, and we look forward to coordinating the next steps required to provide Anzupgo to those patients who need it.”

The US Food and Drug Administration (FDA) has also accepted the company’s new drug application seeking approval for delgocitinib cream.

A topical pan-Janus kinase (JAK) inhibitor, Anzupgo works by addressing the JAK-STAT signalling pathway implicated in CHE’s pathogenesis.

LEO Pharma holds the sole rights for the development and commercialisation of delgocitinib cream for dermatological uses globally, except in Japan, since the signing of a licensing agreement with Japan Tobacco in 2014.

Japan Tobacco holds the rights to the asset in Japan.

LEO Pharma chief development officer Kreesten Meldgaard Madsen stated: “This approval is the culmination of years of focus and effort, driven every day by the goal to support this patient population.

“The new treatment option aims to support the management of this debilitating condition, given the limited treatment options for CHE currently approved across Europe.”

In June 2024, Leo Pharma received FDA approval for Adbry (tralokinumab-ldrm) single-dose autoinjector for atopic dermatitis.

Source: pharmaceutical-technology.com

comments closed

Related News

October 6, 2024

Meet Rosalie Harrison, Borderless Life Sciences Partner at CPHI Milan

Life sciences

“There’s no better place to meet our industry partners in person and get a first-hand feel for the state of the pharma industry than at CPHI,” says Borderless Partner Rosalie Harrison, who leads the firm’s life sciences practice.

October 6, 2024

Boehringer Ingelheim expands cancer research at Vienna Site

Life sciences

On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to Boehringer Ingelheim, the investment of around €60 million is further proof of the company’s commitment to cancer research.

October 6, 2024

Lilly announces new $4.5 Billion site

Life sciences

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. The facility will enable Lilly to research new methods of producing medicines and scale up manufacturing for clinical trials.